Vaccine approval does not guarantee equitable access. Critically examine this statement with reference to India's dengue vaccination strategy.

Q. Vaccine approval does not guarantee equitable access. Critically examine this statement with reference to India's dengue vaccination strategy. (15 marks, 250-350 words)

The CDSCO's marketing authorisation for Qdenga (TAK-003), a live-attenuated tetravalent dengue vaccine of Takeda GmbH, is India's first dengue vaccine approval [1]. Yet regulatory clearance is a scientific and legal milestone, not a delivery guarantee — equitable access depends on price, procurement channel and programme integration.

Where approval does advance access - Regulatory credibility: approval followed a pivotal Phase III study in Indians aged 4–60 years and licensure in 40-plus countries, easing safety hesitancy [1]. - Global assurance: WHO prequalification (2024) opens UN/donor procurement routes and signals manufacturing quality [2]. - No screening barrier: unlike Dengvaxia, Qdenga needs no pre-vaccination serostatus test, removing a costly gatekeeping step for poorer users. - Domestic pipeline: ICMR–Panacea Biotec's indigenous DengiAll, in a Phase 3 trial across 19 sites with over 10,000 participants, promises future price competition [3].

Why approval alone cannot ensure equity - Pricing and channel: approval says nothing on cost; a private-market rollout favours urban, insured households, while Aedes vectors are now spreading into semi-urban and rural districts with weaker surveillance. - No programmatic mandate: inclusion in the National Centre for Vector Borne Diseases Control framework or the Universal Immunisation Programme requires a separate NTAGI-type policy decision, budget line and cold-chain expansion [4]. - Serotype uncertainty: protection is strongest against DENV-2 and DENV-1 but uncertain against DENV-3 and DENV-4 in dengue-naïve persons — rising DENV-3 circulation could blunt real-world benefit. - Trust deficit: the Dengvaxia episode in the Philippines (2017) shows that weak risk communication and post-marketing surveillance can collapse uptake among the very poor.

Thus the statement holds: approval is necessary but insufficient. Equity demands transparent price negotiation, phased public procurement targeting high-burden districts, robust post-marketing surveillance, and continued vector control — vaccination complementing, not replacing, it. Pairing Qdenga with an affordable indigenous vaccine would align India's dengue strategy with SDG-3 and the constitutional promise of health under Article 21.

(~330 words)

Sources: 1. CDSCO Approves India's First Dengue Vaccine, Strengthening National Dengue Prevention Efforts — PIB — first Indian approval, Takeda GmbH, TAK-003, ages 4–60, prior licensure abroad 2. Qdenga® — WHO Prequalification of Medical Products — WHO prequalification status and manufacturing/regulatory details 3. ICMR and Panacea Biotec initiate the First Dengue Vaccine Phase 3 Clinical Trial in India with Indigenous Dengue Vaccine, DengiAll — PIB — indigenous candidate, 19 sites, 10,000+ participants 4. National Center for Vector Borne Diseases Control (NCVBDC), MoHFW — nodal programme framework for dengue prevention and control